These compounds, in strong contrast to first-generation and second-generation p38α inhibitors, faithfully resemble phenotypes obtained after genetic knockdown of Mapk14 and show marked therapeutic efficacy in CRC mouse models and patient-derived CRC organoids as a monotherapy. The gene discussed is MAPK14; the disease is colorectal carcinoma.